Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the clinical trial milestones, cash-runway estimates, and dilution risks hidden inside Adaptimmune’s dense disclosures can feel like analyzing lab results without a microscope. Our dedicated SEC page solves that problem by turning every page—whether a 300-page 10-K or a same-day 8-K—into a clear narrative. If you have ever searched for Adaptimmune Therapeutics SEC filings explained simply, you are in the right place.
Stock Titan’s AI reads each document the moment it reaches EDGAR, then serves concise summaries, red-flag alerts, and side-by-side comparisons. Need the next Adaptimmune Therapeutics quarterly earnings report 10-Q filing? It appears here in real time with an Adaptimmune Therapeutics earnings report filing analysis that highlights R&D burn and partnership revenue shifts. Curious about executive confidence? We tag every Adaptimmune Therapeutics Form 4 insider transactions real-time entry, making it effortless to track Adaptimmune Therapeutics executive stock transactions Form 4 before headlines break.
Our coverage spans every filing type investors rely on:
- Adaptimmune Therapeutics annual report 10-K simplified—spot pipeline progress and cash runway in minutes.
- Adaptimmune Therapeutics 8-K material events explained—follow trial pauses, partnership updates, or financings as they post.
- Adaptimmune Therapeutics proxy statement executive compensation—understand incentive alignment without decoding legalese.
- Adaptimmune Therapeutics insider trading Form 4 transactions—monitor insider buying or selling patterns instantly.
Whether you are understanding Adaptimmune Therapeutics SEC documents with AI for a trade idea or building a long-term oncology thesis, our platform equips you to act quickly and confidently. Complex cell-therapy disclosures clarified—no biotech PhD required.
Adaptimmune Therapeutics (ADAP) has agreed to sell its four autologous T-cell therapy programs—TECELRA, lete-cel, afami-cel and uza-cel—to US WorldMeds for $55 million cash at closing plus up to $30 million in regulatory and commercial milestones.
Proceeds will immediately repay the company’s outstanding Hercules Capital loan. US WorldMeds will assume selected liabilities, acquire manufacturing assets, licences and regulatory files, and offer jobs to roughly half of Adaptimmune’s staff. Adaptimmune will provide transition services through 30 June 2026.
Restructuring: Following the deal, Adaptimmune plans to cut its remaining workforce by �62 %, booking $7�8 million in severance costs (mainly Q3-25). Senior leaders—including the Chief Medical, Commercial, Scientific and Financial Officers—will depart in August 2025.
The transaction must close by 4 Aug 2025, subject to customary conditions and the absence of any material adverse effect.
- $5 M on FDA BLA acceptance for lete-cel
- $10 M on FDA approval for lete-cel
- Up to $5 M if TECELRA quarterly U.S. sales �$18 M
- $10 M if combined U.S. sales of TECELRA & lete-cel �$200 M
FAQ
What is the current stock price of Adaptimmune Therapeutics Plc (ADAP)?
What is the market cap of Adaptimmune Therapeutics Plc (ADAP)?
What is the core focus of Adaptimmune Therapeutics PLC?
How does Adaptimmune’s TCR platform work?
What are the main therapeutic areas addressed by Adaptimmune?
How does Adaptimmune generate value in the biopharmaceutical industry?
What distinguishes Adaptimmune in the competitive immunotherapy landscape?
How does the company approach research and development?
What role do strategic collaborations play for Adaptimmune?
What information can investors expect to find in Adaptimmune’s company overview?
